A new therapeutic protein has been designed by the scientists that have the potential to target the receptors which are commonly found on the surface of weak cells linked to the improvement of a number of diseases, covering cancer. The hopes are high in terms of this new protein being discovered and the way it binds to the cells; carry the potential of leading you to new, more and effective treatments.
ProAgio is the name given to this protein which is generated from a human protein. It targets the transmembrane receptor on the cells surface called as an integrin that enables them to interact with one another. The receptor ProAgio explores out integrin αVβ₃, a molecule that helps the scientists as a focus for medicines
This molecule isn’t unique to any type of unhealthy cells and is basically expressed in the cells of new blood vessels, macrophages or the immune cells and bone cells.
A process called ligand binding has been developed by the scientists previously that hone in on αVβ₃ by docking with the integrin by a form of chemical bonding. But in any case, this kind of techs haven’t been so very successful, therefore, a different approach was adopted.
The enzyme recruited by ProAgio is known by the name of caspase 8 which plays a significant role in apoptosis, the programmed cell death. It can also be said that by targeting cells which bear the αVβ₃ receptors, ProAgio initially enlists caspase 8 and provides cells that stand a good chance of going cancerous to self-destruct.